Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report

Abstract We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhib...

Full description

Bibliographic Details
Main Authors: Tomonori Makiguchi, Takashi Fukushima, Hisashi Tanaka, Kageaki Taima, Shinobu Takayasu, Sadatomo Tasaka
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Thoracic Cancer
Subjects:
COVID‐19 vaccination
diabetic ketoacidosis
immune checkpoint inhibitor
immune‐related adverse event
Online Access:https://doi.org/10.1111/1759-7714.14352

Similar Items

Similar Items